Skip to main content
Solasia Pharma K.K. logo

Solasia Pharma K.K. — Investor Relations & Filings

Ticker · 4597 ISIN · JP3436500007 LEI · 529900A8W8K4LULTG564 T Manufacturing
Open in API
Filings indexed 62 across all filing types
Latest filing 2024-05-15 Interim / Quarterly Rep…
Country JP Japan
Listing T 4597

About Solasia Pharma K.K.

https://solasia.co.jp/en/

Solasia Pharma K.K. is a specialty pharmaceutical company focused on oncology. The company's business model involves in-licensing promising drug candidates to develop and commercialize them for patients in Asian markets. Its portfolio is centered on addressing unmet medical needs in both cancer treatment and supportive care, aiming to improve patients' quality of life. Key commercialized products include Sancuso® for chemotherapy-induced nausea and vomiting (CINV), DARVIAS® for peripheral T-cell lymphoma (PTCL), and episil® oral liquid, a medical device for pain associated with oral mucositis. The development pipeline includes candidates for treating chemotherapy-induced peripheral neuropathy (CIPN) and colorectal cancer.

Recent filings

Filing Released Lang Actions
四半期報告書－第17期第1四半期(2024/01/01－2024/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Solasia Pharma K.K. covering the period from January 1, 2024, to March 31, 2024. It contains detailed financial statements, management analysis (MDA), and information on share capital and stock options. It is a formal regulatory filing submitted to the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. As it is a comprehensive quarterly financial report, it falls under the 'Interim / Quarterly Report' category. Q1 2024
2024-05-15 Japanese
臨時報告書
AGM Information Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and explicitly states in Section 1 that it is being submitted based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act because resolutions were passed at the Annual General Meeting (AGM) held on March 22, 2024. Section 2 details the resolutions, which concern the election of directors and auditors. This content—reporting the results of shareholder votes from a general meeting—directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements'. The code for this is DVA.
2024-03-26 Japanese
内部統制報告書－第16期(2023/01/01－2023/12/31)
Governance Information Classification · 100% confidence The document is explicitly titled "内部統制報告書" (Internal Control Report) in the header and within the table structure. It references the legal basis as "金融商品取引法第24条の４の４第１項" (Article 24-4-4, Paragraph 1 of the Financial Instruments and Exchange Act), which mandates the filing of an Internal Control Report in Japan. The content discusses the framework, scope, criteria (using the fiscal year-end date of December 31, 2023), and the conclusion regarding the effectiveness of internal controls over financial reporting. This directly corresponds to the definition of an Audit Report / Information (AR), which covers internal or regulatory stress tests and applied accounting principles, although in this specific Japanese context, the Internal Control Report is a distinct mandatory filing related to financial reporting integrity, fitting best under the AR category among the provided options, as it is a formal report on internal controls rather than a general earnings release (ER) or a full annual report (10-K). Given the specific nature of the filing, AR is the most appropriate classification.
2024-03-22 Japanese
確認書
Regulatory Filings Classification · 95% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification confirming the accuracy of the company's Annual Securities Report (有価証券報告書). According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type, as they do not contain the actual financial statements themselves. FY 2023
2024-03-22 Japanese
有価証券報告書－第16期(2023/01/01－2023/12/31)
Annual Report Classification · 100% confidence The document is a '有価証券報告書' (Yuuka Shouken Houkokusho), which is the Japanese equivalent of an Annual Report (10-K). It contains comprehensive financial statements, management discussion, and corporate information for the fiscal year ending December 31, 2023. It is a full-length regulatory filing, not an announcement or a summary. FY 2023
2024-03-22 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, specifically accompanying a Third Quarter Report (Dai-san shihanki hokokusho). While it references the quarterly report, the document itself is a formal regulatory confirmation statement required by Japanese law for quarterly filings. Since it is a specific regulatory filing document that does not contain the full financial report itself, it falls under the RNS (Regulatory Filings) category as a formal regulatory submission.
2023-11-13 Japanese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.